ENTRY       D02596                      Drug
NAME        Tocilizumab (USAN/INN);
            Tocilizumab (genetical recombination) (JAN);
            Actemra (TN)
PRODUCT     TOCILIZUMAB (Genentech)
FORMULA     C6428H9976N1720O2018S42
EXACT_MASS  144895.9145
MOL_WEIGHT  144985.0322
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
            Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
REMARK      Therapeutic category: 6399
            ATC code: L04AC07
            Product: D02596<JP/US>
EFFICACY    Anti-inflammatory, Antirheumatic, Immunosuppressant, Anti-IL-6 receptor antibody
  DISEASE   Rheumatoid arthritis [DS:H00630]
            Giant Cell Arteritis [DS:H01698]
            Systemic sclerosis-associated interstitial lung disease [DS:H01492]
            Polyarticular juvenile idiopathic arthritis [DS:H01672]
            Systemic juvenile idiopathic arthritis [DS:H01672]
  TYPE      Monoclonal antibody
COMMENT     Treatment of cytokine release syndrome
TARGET      IL6R (CD126) [HSA:3570] [KO:K05055]
  PATHWAY   hsa04060(3570)  Cytokine-cytokine receptor interaction
            hsa04630(3570)  JAK-STAT signaling pathway
            hsa04640(3570)  Hematopoietic cell lineage
INTERACTION  
STR_MAP     map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC07 Tocilizumab
                  D02596  Tocilizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Tocilizumab
                 D02596  Tocilizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D02596  Tocilizumab (USAN/INN); Tocilizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D02596  Tocilizumab
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D02596  Tocilizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D02596  Tocilizumab
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D02596  Tocilizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL6R (CD126)
                 D02596  Tocilizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D02596
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02596
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02596
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D02596
DBLINKS     CAS: 375823-41-9
            PubChem: 17396767
            NIKKAJI: J2.104.935B
///
